Universal reference book for medicines

Active substance: tamoxifen

Type: Antiestrogenic drug with antitumor effect

Manufacturer: ФП ОБОЛЕНСКОЕ (Russia)
Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..

Antitumor agent.
Antiestrogen. It blocks estrogen receptors and thus inhibits the progression of a tumor disease stimulated by estrogens.
Tamoxifen is metabolized in the liver, subjected to intestinal hepatic recirculation.
It is excreted with bile in the form of metabolites.
Breast cancer in women in menopause, breast cancer in men after castration, kidney cancer, melanoma (containing estrogen receptors), ovarian cancer;
Prostate cancer with resistance to other drugs.
The dosage regimen is set individually, depending on the indications, the patient's condition and the antitumor therapy regimen used.

On the part of the digestive system: nausea, vomiting, increased activity of hepatic transaminases;
in some cases - fatty liver infiltration, cholestasis, hepatitis.
From the side of the central nervous system: rarely - depression, dizziness, headache, retrobulbar neuritis.

From the side of the organ of vision: rarely - retinopathy, keratopathy, cataract.

From the hemopoietic system: rarely - thrombocytopenia, leukopenia.

On the part of the endocrine system: in women - endometrial hyperplasia, vaginal bleeding, hot flashes, weight gain;
in men - impotence, decreased libido.
From the cardiovascular system: edema, thromboembolism, phlebitis.

Dermatological reactions: alopecia, rash, itching.

Other: pain in bones and lesions, increase in body temperature.

Thrombophlebitis, pregnancy, hypersensitivity to tamoxifen.

Tamoxifen is contraindicated in pregnancy.
If necessary, use during lactation should stop breastfeeding.
In experimental studies , the teratogenic effect of tamoxifen was established.

Use with caution in leukopenia, thrombocytopenia, hypercalcemia, in patients with cataracts, hyperlipidemia.

During the treatment, the picture of peripheral blood should be monitored regularly (especially the number of platelets);
the level of calcium and glucose in the blood;with prolonged use, the observation of the oculist (every 3 months) is shown.
Do not combine with drugs that contain hormones, especially estrogens.

When used simultaneously with drugs that affect the blood coagulation system, tamoxifen dosage adjustment is necessary.

In experimental studies , the carcinogenic effect of tamoxifen was established.

With the simultaneous use of anticoagulants with coumarin derivatives, the risk of an anticoagulant effect increases;
with cytostatics - there may be an increased risk of thrombosis.
With simultaneous application with allopurinol, hepatotoxic effect is possible;
with aminoglutethimide - a decrease in the concentration of tamoxifen in the plasma, apparently due to an increase in its metabolism.
In patients receiving tamoxifen, prolongation of neuromuscular blockade caused by atracurium is possible.

With the simultaneous use of bromocriptine, it is possible to enhance the dopaminergic effect of bromocriptine.

In patients receiving tamoxifen, with the use of warfarin, there is a risk of developing a threatening clinical situation: prolongation of prothrombin time, hematuria, hematoma is possible.

With simultaneous use with mitomycin, the risk of hemolytic-uremic syndrome increases.

It is possible to reduce the concentration of tamoxifen in the blood plasma, which, apparently, is due to the induction of the isoenzyme CYP3A4 under the action of rifampicin.

Estrogens can reduce the therapeutic effect of tamoxifen.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!